Funding for this research was provided by:
Wellcome (108785/Z/15/Z, 106130/Z/14/Z)
Medical Research Council (MC_uu_12009)
Received: 4 September 2020
Accepted: 12 June 2021
First Online: 21 July 2021
: J.R.H. and J.O.J.D. are founders and shareholder of Nucleome Therapeutics and D.J.D. is a paid consultant for Nucleome Therapeutics. Other authors declare no competing interests.